Ryvu Therapeutics SA(DE:9Y4)
€3.54-0.01 (-0.28%)
DE:9Y4
Ryvu Therapeutics SA stock drug pipeline
€3.54
At close:-0.01 (-0.28%)
Ryvu Therapeutics SA (9Y4) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Rvu120 | Advanced Solid Tumors, High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukaemia (Aml) | Phase II | Not Yet Recruiting | RVU120 Rollover Study | May 15, 2025 | ― |
| Men1703, Glofitamab | Non-Hodgkin Lymphoma, B-Cell | Phase II | Recruiting | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Jul 30, 2024 | ― |
| Ruxolitinib, Rvu120 | Myelofibrosis | Phase II | Recruiting | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis | Apr 29, 2024 | ― |
| Rvu120 (Sel120) | Low Risk Myelodysplastic Syndromes | Phase II | Active Not Recruiting | RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms | Jan 25, 2024 | ― |
| Rvu120 | Acute Myeloid Leukemia (Aml), High-Risk Myelodysplastic Syndrome | Phase II | Active Not Recruiting | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML | Jan 05, 2024 | ― |
| Venetoclax, Rvu120 | Acute Myeloid Leukemia | Phase II | Recruiting | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | Dec 19, 2023 | ― |
| Rvu120 | Advanced Solid Tumor | phase1AndPhase2 | Active Not Recruiting | RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors | Sep 07, 2021 | ― |
| Rvu120(Sel120) | Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome | Phase I | Active Not Recruiting | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Jul 12, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Rvu120 | Phase II | Advanced Solid Tumors, High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukaemia (Aml) | Not Yet Recruiting | RVU120 Rollover Study | May 15, 2025 | ― |
| Men1703, Glofitamab | Phase II | Non-Hodgkin Lymphoma, B-Cell | Recruiting | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) | Jul 30, 2024 | ― |
| Ruxolitinib, Rvu120 | Phase II | Myelofibrosis | Recruiting | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis | Apr 29, 2024 | ― |
| Rvu120 (Sel120) | Phase II | Low Risk Myelodysplastic Syndromes | Active Not Recruiting | RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms | Jan 25, 2024 | ― |
| Rvu120 | Phase II | Acute Myeloid Leukemia (Aml), High-Risk Myelodysplastic Syndrome | Active Not Recruiting | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML | Jan 05, 2024 | ― |
| Venetoclax, Rvu120 | Phase II | Acute Myeloid Leukemia | Recruiting | Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML | Dec 19, 2023 | ― |
| Rvu120 | phase1AndPhase2 | Advanced Solid Tumor | Active Not Recruiting | RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors | Sep 07, 2021 | ― |
| Rvu120(Sel120) | Phase I | Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome | Active Not Recruiting | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Jul 12, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Ryvu Therapeutics SA (DE:9Y4) have in its pipeline
Ryvu Therapeutics SA DE:9Y4 is currently developing the following drugs: Rvu120, Men1703, Glofitamab, Ruxolitinib, Rvu120, Rvu120 (Sel120), Venetoclax, Rvu120, Rvu120(Sel120). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
